Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

A. Gronchi

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Management of Soft Tissue and Visceral Leiomyosarcomas.

Importance Leiomyosarcoma is a rare and heterogeneous malignant mesenchymal neoplasm associated with substantial morbidity and mortality. Given recent advances in biologic understanding and the complexity of leiomyosarcoma, a consensus-driven approach is needed to harmonize management and address remaining clinical and...

F. Campos, R. Gladdy, Annie Achee et al. · 0 citations
Review Sep 2026

Cutting-edge research in surgical oncology: A framework for decision-grade evidence.

Surgical innovation and oncologic practice are evolving rapidly. However, the evidence base supporting many interventions/decisions in surgical oncology remains vulnerable to bias, limited generalizability, and inconsistent reporting. To address this gap, this multidisciplinary review, developed through structured disc...

A. Gronchi, G. Bogani, R. Agresti et al. · 0 citations
Open access Aug 2026

Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma

Dedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal malignancy coexisting with a low grade well-differentiated component. Pathways implicated in liposarcoma growth and dedifferentiation are promoted by heparan sulfate (HS) proteoglycans (HSPG) and their modifying enzymes including heparanase. HSPGs serve...

C. Lanzi, E. Favini, Laura Dal Bo et al. · 0 citations
Open access Aug 2026

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

Findings identify failure to accumulate H3K27 acetylation as a hallmark of resistance to EZH2 inhibition-based treatment, and show that pharmacological HDAC inhibition can restore this chromatin transition and re-sensitize resistant tumors, providing a rationale for combined epigenetic targeting strategies in INI1-defi...

N. Arrighetti, C. Soffientini, V. Zuco et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.